Macquarie Group LTD Bio N Tech Se Transaction History

Macquarie Group LTD

$87.4 Billion
Q1 2024

A detailed history of Macquarie Group LTD transactions in Bio N Tech Se stock. As of the latest transaction made, Macquarie Group LTD holds 37,263 shares of BNTX stock, worth $2.93 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

37,263

Previous 38,404 2.97%

Holding current value

$2.93 Million

Previous $4.05 Million 15.2%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$88.96 - $112.35 $101,503 - $128,191	-1,141 Reduced 2.97%	37,263 $3.44 Million
Q4 2023 Feb 14, 2024	SELL	$90.91 - $112.75 $212,911 - $264,060	-2,342 Reduced 5.75%	38,404 $4.05 Million
Q2 2023 Aug 14, 2023	BUY	$102.58 - $129.66 $384,880 - $486,484	3,752 Added 10.14%	40,746 $4.4 Million
Q1 2023 May 15, 2023	SELL	$122.57 - $153.67 $477,287 - $598,390	-3,894 Reduced 9.52%	36,994 $4.61 Million
Q4 2022 Feb 21, 2023	BUY	$118.43 - $186.05 $2.77 Million - $4.35 Million	23,375 Added 133.47%	40,888 $6.14 Million

Q3 2022 Nov 14, 2022	BUY	$127.65 - $183.11 $135,947 - $195,012	1,065 Added 6.47%	17,513 $2.36 Million
Q2 2022 Aug 15, 2022	BUY	$123.25 - $186.24 $142,477 - $215,293	1,156 Added 7.56%	16,448 $2.45 Million
Q1 2022 May 16, 2022	BUY	$126.25 - $231.85 $880,341 - $1.62 Million	6,973 Added 83.82%	15,292 $2.61 Million
Q4 2021 Feb 11, 2022	BUY	$216.64 - $362.52 $1.8 Million - $3.02 Million	8,319 New	8,319 $2.15 Million
Q3 2021 Nov 12, 2021	SELL	$205.93 - $447.23 $2.64 Million - $5.73 Million	-12,806 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$113.32 - $241.49 $1.45 Million - $3.09 Million	12,806 New	12,806 $2.87 Million

Others Institutions Holding BNTX

# of Institutions

326

Shares Held

40.4M

Call Options Held

1.31M

Put Options Held

1.37M

View Full List

About BioNTech SE

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $19.1B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

More about BNTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.

Account

Macquarie Group LTD Bio N Tech Se Transaction History